Page 79 - CIBEREHD2016-ENG

Most relevant scientific articles
• Hernández-Bartolomé Á, López-Rodríguez R, García-Buey L, Martín-Vílchez S, Rodríguez-Muñoz Y, Borque MJ et al. Intrahepatic angiopoietin-2 correlates with chronic hepatitis C progression and is induced in hepatitis C virus replicon systems. Liver international: official journal of the International Association for the Study of the Liver. 2016.
• Hernández-Bartolome A., Lopez-Rodriguez R., Borque M.J., Gonzalez-Moreno L., Real-Martinez Y., Garcia-Buey L. et al. Angiopoietin-2/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C. World Journal of Gastroenterology. 2016;22(44):9744-9751.
• Madejon A., Romero M., Hernández A., Garcia-Sanchez A., Sanchez-Carrillo M., Olveira A. et al. Hepatitis B and D viruses replication interference: Influence of hepatitis B genotype. World Journal of Gastroenterology. 2016;22(11):3165-3174.
• Martin-Dominguez V., Diaz-Menendez A., Santander C., Garcia-Buey L.C. Portal hypertensive polyps, a new entity? Revista Espanola de Enfermedades Digestivas. 2016;108(5):279-280.
Hightlights
During last year we have been mainly focused on investigating the impact of Hepatitis C Virus (HCV)
on the expression of angiopoietins (Ang1 and Ang2) by hepatocytes, the meaning of these factors on chronic hepatitis C (CHC) progression and the possible involved signaling routes. Interestingly, our recent findings have shown that intrahepatic levels of Ang2 significantly correlate with the necro-inflammatory activity index of the liver as well as with the fibrosis stage of CHC patients. Furthermore, the in vitro expression of Ang2 by different HCV replicons was notably stimulated by the influence of either structural or nonstructural HCV genomic regions but encouragingly reduced by the inhibition of PI3K signaling, highlighting its relevance as a target for therapeutic intervention.
Furthermore, concerning to the HCV strategic line of CIBEREHD we have been studying potential immune factors related to the emergence/recurrence of hepatic and extrahepatic manifestations associated with chronic HCV infection after direct acting antivirals (DAA) therapy. Despite this treatment causes a significant reduction of these complications, not all patients benefit equally, especially those with advanced fibrosis, thus requiring a close monitoring of its progression. In this regard, owing to the central role played by the immune system in the therapeutic response and the appearance of various disorders associated with CHC, we are monitoring the peripheral immunologic profile of patients before, during and after treatment with AADs by a wide cytokine array of more than 100 factors in order to detect any anomalies that help to establish a more accurate prognosis for these patients.
EHD
research Groups 79